NCT02531360 - Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

August 31, 2016

Conditions

Alzheimer's Disease (AD)Progressive Supranuclear Palsy (PSP)Cortical Basal Syndrome (CBS)Frontal Temporal Dementia (FTD)

Interventions

DRUG

[18F]MNI-815 (MNI-815)

All enrolled subjects will undergo an \[18F\]MNI-815 PET imaging visit. As a part of the screening visit, subjects will undergo \[18F\]florbetaben (FBB) PET imaging to determine if they have significant amyloid deposition.

Trial Locations (1)

06510

Molecular NeuroImaging, LLC, New Haven